Page 82 - Medicare Benefit Policy Manual
P. 82

50.6 – Coverage of Intravenous Immune Globulin for Treatment of
                   Primary Immune Deficiency Diseases in the Home
                   (Rev. 259, Issued: 07-12-19, Effective: 08-13-19, Implementation: 08-13-19)

                   The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 provides
                   coverage of intravenous immune globulin (IVIG) for the treatment of primary immune
                   deficiency diseases in the home (ICD-9 diagnosis codes 279.04, 279.05, 279.06, 279.12,
                   and 279.2 or ICD-10-CM codes G11.3, D80.0, D80.2, D80.3, D80.4, D80.5, D80.6,
                   D80.7, D81.0, D81.1, D81.2, D81.5, D81.6, D81.7, D81.89, D81.9, D82.0, D82.1, D82.4,
                   D83.0, D83.1, D83.2, D83.8, or D83.9 if only an unspecified diagnosis is necessary). The
                   Act defines “intravenous immune globulin” as an approved pooled plasma derivative for
                   the treatment of primary immune deficiency disease.  It is covered under this benefit
                   when the patient has a diagnosed primary immune deficiency disease, it is administered
                   in the home of a patient with a diagnosed primary immune deficiency disease, and the
                   physician determines that administration of the derivative in the patient’s home is
                   medically appropriate.  The benefit does not include coverage for items or services
                   related to the administration of the derivative.  For coverage of IVIG under this benefit, it
                   is not necessary for the derivative to be administered through a piece of durable medical
                   equipment.

                   60 - Services and Supplies Furnished Incident To a Physician’s/NPP’s
                   Professional Service
                   (Rev. 1, 10-01-03)
                   B3-2050

                   A - Noninstitutional Setting

                   For purposes of this section a noninstitutional setting means all settings other than a
                   hospital or skilled nursing facility

                   Medicare pays for services and supplies (including drug and biologicals which are not
                   usually self-administered) that are furnished incident to a physician’s or other
                   practitioner’s services, are commonly included in the physician’s or practitioner’s bills,
                   and for which payment is not made under a separate benefit category listed in §1861(s) of
                   the Act. A/B MACs (A) and (B) must not apply incident to requirements to services
                   having their own benefit category. Rather, these services should meet the requirements of
                   their own benefit category. For example, diagnostic tests are covered under §1861(s)(3)
                   of the Act and are subject to their own coverage requirements. Depending on the
                   particular tests, the supervision requirement for diagnostic tests or other services may be
                   more or less stringent than supervision requirements for services and supplies furnished
                   incident to physician’s or other practitioner’s services. Diagnostic tests need not also
                   meet the incident to requirement in this section. Likewise, pneumococcal, influenza, and
                   hepatitis B vaccines are covered under §1861(s)(10) of the Act and need not also meet
                   incident to requirements. (Physician assistants, nurse practitioners, clinical nurse
                   specialists, certified nurse midwives, clinical psychologists, clinical social workers,
                   physical therapists and occupational therapists all have their own benefit categories and
   77   78   79   80   81   82   83   84   85   86   87